Trexquant Investment LP bought a new stake in Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 64,908 shares of the biotechnology company's stock, valued at approximately $2,612,000. Trexquant Investment LP owned approximately 0.06% of Viking Therapeutics as of its most recent SEC filing.
Several other institutional investors have also modified their holdings of VKTX. Blue Trust Inc. increased its position in Viking Therapeutics by 75.9% during the fourth quarter. Blue Trust Inc. now owns 716 shares of the biotechnology company's stock worth $29,000 after purchasing an additional 309 shares during the last quarter. YANKCOM Partnership purchased a new stake in shares of Viking Therapeutics in the 4th quarter valued at approximately $33,000. CIBC Private Wealth Group LLC raised its position in shares of Viking Therapeutics by 170.2% during the 4th quarter. CIBC Private Wealth Group LLC now owns 1,351 shares of the biotechnology company's stock valued at $55,000 after buying an additional 851 shares during the period. S.A. Mason LLC lifted its holdings in Viking Therapeutics by 20.0% in the fourth quarter. S.A. Mason LLC now owns 1,800 shares of the biotechnology company's stock valued at $72,000 after acquiring an additional 300 shares during the last quarter. Finally, Wolff Wiese Magana LLC purchased a new position in Viking Therapeutics in the fourth quarter worth approximately $75,000. Hedge funds and other institutional investors own 76.03% of the company's stock.
Insider Activity at Viking Therapeutics
In related news, Director Sarah Kathryn Rouan acquired 1,240 shares of Viking Therapeutics stock in a transaction dated Monday, March 31st. The stock was acquired at an average price of $24.15 per share, for a total transaction of $29,946.00. Following the transaction, the director now owns 1,240 shares of the company's stock, valued at $29,946. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 4.70% of the stock is currently owned by corporate insiders.
Wall Street Analyst Weigh In
VKTX has been the topic of several recent analyst reports. Citigroup assumed coverage on Viking Therapeutics in a research note on Friday, February 7th. They issued a "neutral" rating and a $38.00 price target on the stock. Maxim Group decreased their target price on shares of Viking Therapeutics from $120.00 to $70.00 and set a "buy" rating on the stock in a research report on Friday, February 7th. Piper Sandler reduced their price target on shares of Viking Therapeutics from $74.00 to $71.00 and set an "overweight" rating on the stock in a research note on Thursday, February 6th. HC Wainwright reiterated a "buy" rating and issued a $102.00 target price on shares of Viking Therapeutics in a report on Wednesday, March 26th. Finally, B. Riley restated a "buy" rating and set a $96.00 price target (down from $109.00) on shares of Viking Therapeutics in a research note on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $89.75.
Check Out Our Latest Research Report on VKTX
Viking Therapeutics Stock Performance
Shares of VKTX traded up $0.70 during midday trading on Friday, hitting $22.22. The company had a trading volume of 2,962,262 shares, compared to its average volume of 3,982,300. The company's 50-day simple moving average is $27.71 and its 200-day simple moving average is $43.20. Viking Therapeutics, Inc. has a 1 year low of $18.92 and a 1 year high of $81.86. The firm has a market capitalization of $2.49 billion, a P/E ratio of -22.22 and a beta of 0.84.
Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last posted its quarterly earnings results on Wednesday, February 5th. The biotechnology company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.05). During the same period in the prior year, the business posted ($0.25) EPS. Equities analysts predict that Viking Therapeutics, Inc. will post -1.56 earnings per share for the current fiscal year.
About Viking Therapeutics
(
Free Report)
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
Featured Articles
Before you consider Viking Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viking Therapeutics wasn't on the list.
While Viking Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
